TAKE Solutions Limited (TAKE.NS)
INR 8.71
(-0.68%)
INR 8.71
(-0.68%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.5 Million INR | -94.61% |
| 2022 | 139.15 Million INR | -49.94% |
| 2021 | 277.97 Million INR | -82.77% |
| 2020 | 1.61 Billion INR | -24.17% |
| 2019 | 2.12 Billion INR | 445.96% |
| 2018 | 389.6 Million INR | -28.58% |
| 2017 | 545.47 Million INR | 11.62% |
| 2016 | 488.67 Million INR | -28.28% |
| 2015 | 681.38 Million INR | 8219.66% |
| 2014 | 8.19 Million INR | -98.58% |
| 2013 | 575.9 Million INR | -30.6% |
| 2012 | 829.79 Million INR | -32.79% |
| 2011 | 1.23 Billion INR | -33.03% |
| 2010 | 1.84 Billion INR | 436.67% |
| 2009 | 343.52 Million INR | 44.18% |
| 2008 | 238.26 Million INR | -20.5% |
| 2007 | 299.71 Million INR | -78.36% |
| 2006 | 1.38 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 93.76 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 7.5 Million INR | -94.61% |
| 2023 Q4 | 7.5 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 137.06 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 139.15 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 139.15 Million INR | -49.94% |
| 2021 Q2 | 1.36 Billion INR | 0.0% |
| 2021 Q4 | 277.97 Million INR | 0.0% |
| 2021 FY | 277.97 Million INR | -82.77% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 1.61 Billion INR | 0.0% |
| 2020 Q2 | 1.87 Billion INR | 0.0% |
| 2020 FY | 1.61 Billion INR | -24.17% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 2.23 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 2.12 Billion INR | 0.0% |
| 2019 FY | 2.12 Billion INR | 445.96% |
| 2018 Q2 | 492.59 Million INR | 0.0% |
| 2018 FY | 389.6 Million INR | -28.58% |
| 2018 Q4 | 389.6 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 495.32 Million INR | 0.0% |
| 2017 FY | 545.47 Million INR | 11.62% |
| 2017 Q4 | 545.47 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 488.67 Million INR | 0.0% |
| 2016 Q2 | 568.25 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 488.67 Million INR | -28.28% |
| 2015 FY | 681.38 Million INR | 8219.66% |
| 2015 Q4 | 681.38 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 437.96 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 175.86 Million INR | 0.0% |
| 2014 FY | 8.19 Million INR | -98.58% |
| 2014 Q4 | 8.19 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 575.9 Million INR | -30.6% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 849.77 Million INR | 0.0% |
| 2013 Q4 | 575.9 Million INR | 0.0% |
| 2012 FY | 829.79 Million INR | -32.79% |
| 2012 Q4 | 829.79 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.12 Billion INR | 0.0% |
| 2011 FY | 1.23 Billion INR | -33.03% |
| 2011 Q4 | 1.23 Billion INR | 0.0% |
| 2010 FY | 1.84 Billion INR | 436.67% |
| 2009 FY | 343.52 Million INR | 44.18% |
| 2008 FY | 238.26 Million INR | -20.5% |
| 2007 FY | 299.71 Million INR | -78.36% |
| 2006 FY | 1.38 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biocon Limited | 129.32 Billion INR | 99.994% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -97.889% |
| Concord Biotech Limited | 18.87 Million INR | 60.254% |
| Dishman Carbogen Amcis Limited | 2.45 Billion INR | 99.695% |
| Jubilant Ingrevia Limited | 4.25 Billion INR | 99.824% |
| Lyka Labs Limited | 429.06 Million INR | 98.252% |
| Panacea Biotec Limited | 209.9 Million INR | 96.427% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.97% |
| SMS Lifesciences India Limited | 331.45 Million INR | 97.737% |
| Supriya Lifescience Limited | 50.2 Million INR | 85.06% |
| Syngene International Limited | 1 Billion INR | 99.25% |
| Zota Health Care Limited | 631.64 Million INR | 98.813% |